News coverage about Aeglea Bio Therapeutics (NASDAQ:AGLE) has trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aeglea Bio Therapeutics earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 44.4036102128865 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Separately, Zacks Investment Research upgraded shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research report on Friday, November 10th.

Shares of Aeglea Bio Therapeutics (NASDAQ AGLE) traded up $0.44 during midday trading on Tuesday, hitting $5.89. 38,200 shares of the company traded hands, compared to its average volume of 81,967. Aeglea Bio Therapeutics has a one year low of $2.81 and a one year high of $8.14. The stock has a market capitalization of $99.35 and a PE ratio of -3.22.

In other Aeglea Bio Therapeutics news, CFO Charles N. York II acquired 6,500 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were acquired at an average price of $4.59 per share, with a total value of $29,835.00. Following the completion of the purchase, the chief financial officer now directly owns 10,828 shares of the company’s stock, valued at approximately $49,700.52. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Anthony G. Quinn acquired 7,956 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The shares were acquired at an average cost of $4.98 per share, for a total transaction of $39,620.88. Following the purchase, the director now directly owns 14,100 shares of the company’s stock, valued at $70,218. The disclosure for this purchase can be found here. Insiders have purchased 57,691 shares of company stock worth $269,483 in the last quarter. 27.00% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Aeglea Bio Therapeutics (AGLE) Receives Coverage Optimism Rating of 0.22” was first reported by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Insider Buying and Selling by Quarter for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with's FREE daily email newsletter.